With +4 years of experience with anti-NGF mAb OA therapies in Europe, and nearly 25M doses of Librela and 8M doses of Solensia delivered globally,¹ together we are making a difference for cats and dogs around the world!
Join us on a 3-part journey as we explore the impact these innovative therapies have made on pets, their owners, and veterinary health teams across the UK.
Full Episodes
Episode 1: A New Era in Canine
OA Pain Control
Episode 2: A New Era in Feline
OA Pain Control
Episode 3: Seeing is Believing: A
New Era in OA Pain Control
Learn about the new era in OA pain control.
LIBRELA IMPORTANT SAFETY INFORMATION:
For use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid selfinjection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be
used in breeding, pregnant or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to
bedinvetmab. The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin
infections and dermatitis. See full Prescribing Information at LibrelaPI.com.
SOLENSIA IMPORTANT SAFETY INFORMATION:
For use in cats only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid selfinjection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Solensia should not be
used in breeding cats or in pregnant or lactating queens. Solensia should not be administered to cats with known
hypersensitivity to frunevetmab. The most common adverse events reported in a clinical study were vomiting and injection
site pain. See full Prescribing Information at
SolensiaPI.com.
